Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland.

BACKGROUND: Penicillin non-susceptible (PNSP) and multi-resistant pneumococci have been prevalent in Iceland since early nineties, mainly causing problems in treatment of acute otitis media. The 10-valent protein conjugated pneumococcal vaccine (PHiD-CV) was introduced into the childhood vaccination program in 2011. The aim of the study was to investigate the changes in antimicrobial susceptibility and serotype distribution of penicillin non-susceptible pneumococci (PNSP) in Iceland 2011-2017. METHODS AND FINDINGS: All pneumococcal isolates identified at the Landspítali University Hospital in 2011-2017, excluding isolates from the nasopharynx and throat were studied. Susceptibility testing was done according to the EUCAST guidelines using disk diffusion with chloramphenicol, erythromycin, clindamycin, tetracycline, trimethoprim/sulfamethoxazole and oxacillin for PNSP screening. Penicillin and ceftriaxone minimum inhibitory concentrations (MIC) were measured for oxacillin resistant isolates using the E-test. Serotyping was done using latex agglutination and/or multiplex PCR. The total number of pneumococcal isolates that met the study criteria was 1,706, of which 516 (30.2%) were PNSP, and declining with time. PNSP isolates of PHiD-CV vaccine serotypes (VT) were 362/516 (70.2%) declining with time, 132/143 (92.3%) in 2011 and 17/54 (31.5%) in 2017. PNSP were most commonly of serotype 19F, 317/516 isolates declining with time, 124/143 in 2011 and 15/54 in 2017. Their number decreased in all age groups, but mainly in the youngest children. PNSP isolates of non PHiD-CV vaccine serotypes (NVT) were 154/516, increasing with time, 11/14, in 2011 and 37/54 in 2017. The most common emerging NVTs in 2011 and 2017 were 6C, 1/143 and 10/54 respectively. CONCLUSIONS: PNSP of VTs have virtually disappeared from children with pneumococcal diseases after the initiation of pneumococcal vaccination in Iceland and a clear herd effect was observed. This was mainly driven by a decrease of PNSP isolates belonging to a serotype 19F multi-resistant lineage. However, emerging multi-resistant NVT isolates are of concern.

Epidemiology of Staphylococcus aureus in neonates on admission to a Chinese neonatal intensive care unit.

PURPOSE: Little is known about the molecular epidemiology of Staphylococcus aureus in Chinese neonatal intensive care units (NICUs). We describe the molecular epidemiology of S. aureus isolated from neonates on admission to Beijing Children's Hospital. METHODS: From May 2015-March 2016, nasal swabs were obtained on admission from 536 neonates. Cultures were also obtained from body sites with suspected infections. S. aureus isolates were characterized by staphylococcal chromosomal cassette (SCCmec) type, staphylococcal protein A (spa) type, multilocus sequence type (MLST), sasX gene, antimicrobial susceptibility and cytotoxicity. Logistic regression assessed risk factors for colonization. RESULTS: Overall, 92 (17%) infants were colonized with S. aureus and 20 (3.7%) were diagnosed with culture-positive S. aureus infection. Of the colonized infants, 70% (64/92) harbored methicillin-susceptible S. aureus (MSSA), 30% (28/92) harbored methicillin-resistant S. aureus (MRSA) while 70% (14/20) of infected infants were culture-positive for MRSA, 30% (6/20) were culture-positive for MSSA. Risk factors for colonization included female sex, age 7-28 days, higher birthweight (3270 IQR [2020-3655] grams) and vaginal delivery (p<0.05). The most common MRSA and MSSA clones were community-associated ST59-SCCmecIVa-t437 (60%) and ST188-t189 (15%), respectively. The sasX gene was not detected. Some MSSA isolates (16%) were penicillin-susceptible and some MRSA isolates (18%) were oxacillin-susceptible. MRSA and MSSA had similar cytotoxicity, but colonizing strains were less cytotoxic than strains associated with infections. CONCLUSIONS: S. aureus colonization was common in infants admitted to our NICU and two community-associated clones predominated. Several non-modifiable risk factors for S. aureus colonization were identified. These results suggest that screening infants for S. aureus upon admission and targeting decolonization of high-risk infants and/or those colonized with high-risk clones could be useful to prevent transmission.

Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study.

BACKGROUND: Invasive pneumococcal disease continues to be a major cause of morbidity and mortality among children younger than 5 years of age in India. We aimed to provide nationally representative data for the pattern of disease due to Streptococcus pneumoniae, trends in the serotype of invasive pneumococci, and invasive pneumococci antimicrobial resistance patterns, in India. METHODS: In this prospective hospital-based and retrospective laboratory-based surveillance study, we prospectively enrolled children aged younger than 5 years with suspected or proven invasive pneumococcal disease from 18 hospitals or institutional centres and retrospectively included laboratory-confirmed pneumococcal isolates from ten sentinel laboratories, together representing 11 states in India. Eligibility criteria were fever higher than 38°C without localising symptoms, clinical presentation of suspected meningitis or pneumonia, and evidence of radiographic pneumonia. We cultured blood and other normally sterile body fluids, reconfirmed and serotyped pneumococcal isolates, and established antimicrobial susceptibility using standard study protocols. FINDINGS: Between Jan 1, 2011, and June 30, 2015, we enrolled 4377 patients. Among 361 (8%) patients with culture-proven pneumococcal disease, all clinical data were known for 226 (63%); among these patients, 132 (58%) presented with pneumonia, 78 (35%) presented with meningitis, and 16 (7%) had other clinical conditions. 131 (3%) died overall and 29 (8%) patients with invasive pneumococcal disease died. Serotypes 14 (52 [14%] of 361), 1 (49 [14%]), 5 (37 [10%]), and 19F (33 [9%]) were the most common. Penicillin non-susceptibility occurred in isolates from 29 (8%) patients, co-trimoxazole resistance occurred in 239 (66%), erythromycin resistance occurred in 132 (37%), and chloramphenicol resistance occurred in 33 (9%). We found multidrug resistance in 33 (9%) of 361 patients. INTERPRETATION: The proportion of positive blood cultures, number of isolates, geographical representation, and data generated over the 4·5 years of the study are representative of data for most of India. Continued surveillance is warranted as the decision to introduce protein conjugated vaccine in India is made. FUNDING: GlaxoSmithKline India.

Emergency department epidemiology of pneumococcal bacteremia in children since the institution of widespread PCV7 vaccination.

BACKGROUND: The heptavalent pneumococcal conjugate vaccine (PCV7) has produced a shift in the epidemiology of invasive infections from Streptoccoccus pneumoniae. OBJECTIVE: Our aim was to determine the temporal changes in pneumococcal bacteremia (Streptococcus pneumoniae bacteremia [SPB]) in the emergency department (ED) since the introduction of PCV7. METHODS: This was a retrospective cohort study of children 0-18 years with SPB evaluated from 1998-2009 in a tertiary-care pediatric ED. The primary outcome was annual proportion of children with SPB from PCV7 serotypes (ie, 4, 6B, 9V, 14, 18C, 19F, and 23F) and nonvaccine serotypes (NVT). Rates of SPB (per 10,000 ED visits) were calculated. SPB was analyzed by time period: before October 2000 was considered "pre-PCV7," November 2000 to October 2003 was considered "peri-PCV7," and after November 2003 was "post-PCV7." Febrile young children (FYC) were defined as children age <36 months and fever without source. RESULTS: A total of 201 episodes of SPB occurred during the study, with a median age of 20.3 months (interquartile range 10.7-49.5 months; range 1.6-215.4 months); 56.7% were male and 69.7% were African American. SPB from PCV7 serotypes decreased more than fourfold, from 82.2% pre-PCV7 to 19.5% peri- and post-PCV7. Most SPB was from NVT serotype 19A (31.3%) peri- and post-PCV7. Annual rates of SPB were 4.01/10,000 ED visits pre-PCV7, decreasing to 2.10 peri-PCV7, and 1.75 post-PCV7. Among the 56 (27.8%) FYC with SPB, NVT were responsible for 11.5% of SPB pre-PCV7, and increased to 80.0% peri- and post-PCV7 (p < 0.001). CONCLUSIONS: Rates of SPB have decreased since the introduction of PCV7, yet SPB still occurs among children in the ED. NVT are increasing in prevalence, and SPB from PCV7-serotypes have decreased.

Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations.

INTRODUCTION: Before the introduction of the heptavalent pneumococcal conjugate vaccine (Prevnar-7), the relative prevalence of serotypes of Streptococcus pneumoniae was fairly stable worldwide. We sought to develop a statistical tool to predict the relative frequency of different serotypes among disease isolates in the pre- and post-Prevnar-7 eras using the limited amount of data that is widely available. METHODS: We initially used pre-Prevnar-7 carriage prevalence and estimates of invasiveness derived from case-fatality data as predictors for the relative abundance of serotypes causing invasive pneumococcal disease during the pre- and post-Prevnar-7 eras, using negative binomial regression. We fit the model to pre-Prevnar-7 invasive pneumococcal disease data from England and Wales and used these data to (1) evaluate the performance of the model using several datasets and (2) evaluate the utility of the country-specific carriage data. We then fit an alternative model that used polysaccharide structure, a correlate of prevalence that does not require country-specific information and could be useful in determining the postvaccine population structure, as a predictor. RESULTS: Predictions from the initial model fit data from several pediatric populations in the pre-Prevnar-7 era. After the introduction of Prevnar-7, the model still had a good negative predictive value, though substantial unexplained variation remained. The alternative model had a good negative predictive value but poor positive predictive value. Both models demonstrate that the pneumococcal population follows a somewhat predictable pattern even after vaccination. CONCLUSIONS: This approach provides a preliminary framework to evaluate the potential patterns and impact of serotypes causing invasive pneumococcal disease.

Annual report of the Australian Meningococcal Surveillance Programme, 2009.

In 2009 there were 233 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the National Neisseria Network, Australia, a nationwide network of reference laboratories. One hundred and thirty-five isolates of Neisseria meningitidis from invasive cases of meningococcal disease were available for which the phenotypes (serogroup, serotype and serosub-type) and/or genotype and antibiotic susceptibility were determined. An additional 98 cases were confirmed by non-culture-based methods (92 by nucleic acid amplification testing (NAAT) and six by serology) , and where possible serotyping was determined. Nationally, 194 (83%) laboratory-confirmed cases where a serogroup was determined were infected with serogroup B and 13 (5.6%) serogroup C meningococci. The national total of confirmed cases has remained relatively stable since 2006, but the number of cases may vary between jurisdictions each year. New South Wales had the highest number of recorded cases in 2009. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia continue to be B:15:P1.7 and B:4:P1.4. Although serogroup C cases were low, phenotype C:2a:P1.5 again predominated in this group. No evidence of meningococcal capsular 'switching' was detected. Approximately two-thirds of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06 to 0.5 mg/L). All isolates remained susceptible to ceftriaxone. Four isolates had reduced susceptibility to ciprofloxacin, and none to rifampicin.

Prevalência de infecção chagásica em doadores de sangue no estado de Pernambuco, Brasil / The prevalence of chagasic infection among blood donors in the State of Pernambuco, Brazil

A doença de Chagas é uma infecção sistêmica de evolução crônica cujo agente etiológico é o parasita Trypanosoma cruzi. O último relato encontrado sobre a soroprevalência da doença em doadores de sangue realizado na capital pernambucana, Recife, data de 1970, onde foi encontrada uma prevalência de 4,4 por cento em doadores de um hospital local. Devido à falta de informações divulgadas sobre a infecção por T. cruzi e sendo Pernambuco uma região endêmica para esta enfermidade, o presente estudo se propôs a analisar o perfil dos doadores de sangue do Hemocentro de Pernambuco (Hemope), que apresentaram reatividade para doença de Chagas, no período de 2002 a 2007. O perfil dos doadores inaptos foi avaliado de acordo com gênero, idade e procedência segundo as mesorregiões de Pernambuco. Foi encontrada uma prevalência de 0,17 por cento para doença de Chagas e 6,89 por cento das bolsas descartadas deveram-se a essa reatividade. Em relação ao gênero dos doadores, foi significativamente maior a contribuição dos homens (p<0,0001). A faixa etária de 18-30 anos apresentou menor quantidade de sorologias reativas (20,21 por cento). Foi verificado também que, na Região Metropolitana do Recife, a quantidade de reações inconclusivas foi estatisticamente maior que a quantidade de sorologias reagentes (p=0,0440). Desta forma, estudos epidemiológicos fornecem dados importantes no sentido de se avaliar diretamente o risco de transmissão de uma doença por transfusão sanguínea e permitem que também em regiões endêmicas se avalie a eficácia das medidas para o controle vetorial.

Chagas disease is a systemic infection with a chronic onset transmitted by Trypanosoma cruzi. The last study conducted in Recife, capital of Pernambuco state, was carried out during 1970. At that time a prevalence of 4.4 percent was found among blood donors of a local hospital. Due to the lack of epidemiology data on T. cruzi infection and as Pernambuco is an endemic region, the present study describes the profile of blood donors who presented reactivity for Chagas disease during the period of 2002 to 2007 in the state's blood bank (Hemope). The profile of unsuitable donors was evaluated according to gender, age and according to the meso-regions of Pernambuco. A prevalence of 0.17 percent was found for Chagas disease, whereas 6.89 percent of the rejected blood bags were due to this reactivity. As far as gender is concerned, the reactivity of men was higher than that of women (p<0.0001). Additionally, the age group between 18-30 years was less infected (20.21 percent). On analyzing the reactivity in each one of the meso-regions of the state, it was found that, in the Metropolitan Region of Recife, the number of inconclusive reaction cases was statistically higher than the number of reactive serology cases (p=0.0440). Thus, epidemiological studies provide important data to indirectly evaluate the risk of blood-borne diseases and allow indirect evaluation of the effectiveness of vectorial control measures in endemic regions.

Asociación entre la colonización materna de Streptococcus del grupo B serotipo III y la rotura prematura de membranas / Association between maternal colonization with serotype III group B Streptococcus and premature rupture of membranes

Objetivo. Examinar la asociación entre la colonización genital de mujeres embarazadas con el serotipo III de Streptococcus del grupo B (SGB) y la rotura prematura de membranas (RPM) en comparación con el resto de los serotipos de SGB. Material y métodos. Por medio de un estudio de cohorte retrospectiva se serotipificaron cepas de SGB de mujeres embarazadas. Se definieron dos grupos: expuestos, pacientes en las que se documentó SGB serotipo III en cultivos vaginales o urinarios, y no expuestos, pacientes en las que se documentó cualquier serotipo diferente al III de SGB, en cultivos vaginales o urinarios. Resultados. Se serotipificaron 135 cepas de SGB: en el grupo de los expuestos se incluyó a 43 mujeres embarazadas, mientras que en el de los no expuestos se incluyó a 92 mujeres. Se documentó RPM en 27 pacientes expuestas (62,7%) y en 17 pacientes no expuestas (18,4%) (RR = 3,3; IC del 95%, 1,2-7; p < 0,05). Conclusiones. El serotipo III se asocia tres veces a RPM (AU)

Objective. To examine the association between maternal colonization with serotype III group B Streptococcus (GBS) and premature rupture of membranes (PROM) in comparison with other GBS serotypes. Material and method. We performed a retrospective cohort study. GBS strains were serotyped in pregnant women. The women were divided into 2 groups: group I consisted of patients with a positive vaginal or urinary culture for GBS serotype III and group II consisted of patients with a positive culture for serotypes Ia, Ib, II, IV, V or VI. Results. There were 135 GBS isolations. Group 1 included 43 pregnant women and group 2 included 92 pregnant women. PROM occurred in 27 patients in group I (62.7%) and in 17 patients in group 2 (18.4%) (RR = 3.3; 95% CI, 1.2-7.4; p < 0.05). Conclusions. Vaginal colonization with serotype III of GBS was associated with a 3-fold increase in the risk of PROM (AU)

Consecutive use of two multiplex PCR-based assays for simultaneous identification and determination of capsular status of nine common Neisseria meningitidis serogroups associated with invasive disease.

We developed two Neisseria meningitidis multiplex PCR assays to be used consecutively that allow determination of the serogroup and capsular status of serogroup A, B, C, 29E, W135, X, and Y cnl-3/cnl-1-like-containing N. meningitidis isolates by direct analysis of the amplicon size. These assays offer a rapid and simple method of serogrouping N. meningitidis.

Antimicrobial resistance and phage types of human and non-human Salmonella enterica isolates in Ireland, 1998-2003.

Between 1998 and 2003, 5,161 isolates (3,182 human) of Salmonella enterica were received by the National Salmonella Reference Laboratory of Ireland. Serotyping, antimicrobial susceptibility testing and phage typing were performed by standard methods. The number of isolates of S. enterica serovar Typhimurium decreased from 579 (80%) in 1998 to 208 (19%) in 2003, while S. enterica serovar Enteritidis increased from 59 (8%) in 1998 to 219 (20%) in 2003. Definitive (DT) phage types 104 and DT104b accounted for a declining proportion of all Salmonella Typhimurium isolates (from n = 523 [90%] in 1998 to 126 [60%] in 2003). Numbers of Salmonella Enteritidis phage type 4 declined from 50 (85%) in 1998 to 59 (27%) in 2003. Twenty-eight isolates of typhoidal Salmonella were received with a history of recent travel in 17 cases. Resistance to multiple (four or more) antimicrobial agents was related to serotype and, where applicable, phage type, and was common in Salmonella Typhimurium. Salmonella Typhimurium predominated among isolates from cattle and pigs (n = 213 [58%]), while Salmonella Livingstone (n = 327) and S. Kentucky (n = 227) were predominant in isolates from poultry (total n = 554 [43%]). This paper discusses trends, and their implications, in Irish salmonella isolates since the establishment of the Reference Laboratory.

Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996.

Streptococcus pneumoniae is the most common cause of invasive bacterial disease among children worldwide. The authors aimed to determine the incidence, clinical characteristics, and serotype distribution of invasive pneumococcal disease (IPD) among Navajo children in the southwestern United States. Active population-based laboratory surveillance for IPD among resident members of the Navajo Nation under 18 years of age was conducted between 1989 and 1996. During this 8-year period, 706 cases of IPD were identified. The rate of disease varied by age, with the highest rate being observed among children aged 6-11 months (727 cases/100,000 person-years), followed by children aged 0-11 months, 0-23 months, and 0-59 months (568, 537, and 272 cases/100,000 person-years, respectively). Among children aged 0-23 months, 60.3% of cases were caused by serotypes in the seven-valent conjugate pneumococcal vaccine (71.5% from 1989-1993 and 58.3% from 1994-1996). Navajo children are at increased risk of IPD in comparison with the general US population. The distribution of disease-causing serotypes is similar to that of many countries in the developing world. Prevention strategies should include the use of licensed pneumococcal protein conjugate vaccine; however, a substantial proportion of disease is caused by nonvaccine serotypes. These data are critical for assessing the impact of these vaccines in this high-risk population.

Annual report of the Australian Meningococcal Surveillance Programme, 2002.

Since 1994, The National Neisseria Network, a nationwide collaborative laboratory program, has examined and analysed isolates of Neisseria meningitidis from cases of invasive meningococcal disease in Australia. The phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility of 393 isolates of N. meningitidis from invasive cases of meningococcal disease were determined in 2002. Most disease was caused by serogroup B (210 isolates, 53%) or serogroup C (162 isolates, 41%) meningococci. An increased number of isolates in Victoria (129 from 77 in 2001) accounted for most of the increased national total. A diversity of phenotypes circulated in the different states and territories. Serogroup B strains predominated in all jurisdictions except Victoria, Tasmania and the Australian Capital Territory and were isolated from sporadic cases of invasive disease. Serogroup B phenotypes B:4:P1.4(7) and B:15:P1.7 were the most common and widely distributed. The common serogroup C phenotype in Victoria, C:2a:P1.4(7), was also common in Tasmania. Elsewhere in Australia it was detected only in low numbers. Other C:2a serosubtypes were prominent in other jurisdictions. About two-thirds of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06 to 0.5 mg/L). Two isolates, one each from Darwin and Sydney, had MICs of 1 mg/L. From 1999, reports have also included diagnoses made by non-culture-based methods in these analyses. Data relating to 187 laboratory-confirmed but culture-negative cases supplemented information on culture confirmed cases in this report.

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).

OBJECTIVES: To detect relatedness among 68 (0.5%) of 13 795 US clinical isolates of Streptococcus pneumoniae from the TRUST 3 (1998-1999) and TRUST 4 (1999-2000) surveillance studies that were resistant to levofloxacin (MIC > or = 8 mg/l). METHODS: All levofloxacin-resistant isolates were analysed by broth microdilution reference method for susceptibility to four fluoroquinolones, DNA sequencing of quinolone resistance determining region (QRDR) of topoisomerase IV and DNA gyrase genes, serotyping, and pulsed-field gel electrophoresis (PFGE). RESULTS: All levofloxacin-resistant isolates were ciprofloxacin resistant (MIC > or = 4 mg/l, FDA breakpoint) and non-susceptible to gatifloxacin (MIC > or = 2 mg/l); 62 were non-susceptible to moxifloxacin (MIC > or = 2 mg/l). Resistant isolates were in 48 (20%) of 238 institutions in 29 states. Three institutions had levofloxacin-resistant isolates in both surveillance studies. Among the resistant isolates were 17 serotypes and 48 different PFGE patterns. Fourteen isolates had PFGE patterns closely related to the Spain(23F)-1 clone; one strain had a PFGE pattern closely related to the French(9V)-3 clone. All levofloxacin-resistant isolates had two or more mutations within the QRDR of parC, parE, gyrA and gyrB. CONCLUSIONS: US levofloxacin-resistant S. pneumoniae isolates were rare and most were unrelated with minimal clonal spread, and were associated with multiple QRDR mutations with extensive cross-resistance noted among fluoroquinolones.

Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy.

In order to evaluate the theoretic coverage of the heptavalent conjugate vaccine against community-acquired pneumonia (CAP) during the first years of life, the anti-capsular IgG antibodies to the nine more common pneumococcal serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F) were quantitated in 196 affected children aged 2-5 years by means of enzyme-linked immunosorbent assays of acute and convalescent serum samples. Acute Streptococcus pneumoniae infection associated with the nine tested serotypes was diagnosed in 57 children (29.1%). Serological data indicated that 16.8% of CAPs were caused by serotypes included in the heptavalent conjugate vaccine. This study confirms the significant role of S. pneumoniae in pediatric CAP, and highlights the importance of pneumococcal conjugate vaccines in preventing it during the first years of life.

Evaluation of a new serotyping assay for detection of anti-hepatitis C virus type-specific antibodies in serum samples.

The performance of a new version (HC03) of the hepatitis C virus (HCV) serotyping 1-6 assay (Abbott Murex Laboratories), a specific test for serological determination of HCV types, was evaluated using a selected panel of 180 HCV RNA-positive sera. HC03 was more sensitive than the current HC02 version, typing 53 (37.6%) of 141 samples which were not typable with HC02. Furthermore, the HC03 specificity was 94.1% as evaluated with a panel of 22 genotyped samples. This new version of the test improves the quality of the serological approach to HCV type determination.

Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones.

Twenty-nine fluoroquinolone (FQ)-resistant clinical isolates of Streptococcus pneumoniae from a collection of isolates from the Alexander Project (1992-1997) and a study from Northern Ireland were identified on the basis of ofloxacin MICs > or = 4 mg/L. DNA fingerprint analyses using BOX-fingerprinting and pulsed-field gel electrophoresis revealed serotype 9V and 23F high-level FQ-resistant strains indistinguishable from the pandemic Spain(23F)-1 and Spain(9V)-3 clones, the type strains of which are low-level resistant or susceptible to the fluoroquinolones.

Antimicrobial susceptibility and pneumococcal serotypes.

The increase in antibiotic resistance and the possible changes in serotype prevalence as a consequence of a new conjugated vaccine have contributed to renewed interest in the study of pneumococcal serotypes and their antibiotic resistances. Spain still has one of the highest penicillin resistance rates, but in the past 4-5 years a slight decrease has been observed. The level of resistance has not increased either, 12.7% of the 11 165 isolates studied showed high-level penicillin resistance but 94% of these had an MIC of only 2 mg/L. Serotypes 6, 9, 14, 19 and 23 included 83% of the penicillin-resistant pneumococci; the remaining 17% belonged to 18 different serotypes. We analysed these minor penicillin-resistant serotypes in view of their potential increase following a possible child vaccination programme. Four of these serotypes (11, 15, 21 and 35) were the most prevalent, and among them serotype 15 was particularly frequent with >50% of its strains resistant. The effective control of these minor penicillin-resistant serotypes should be based on continuous surveillance of pneumococcal epidemiology.

Serotype prevalence of occult pneumococcal bacteremia.

OBJECTIVE: The licensure and use of a pneumococcal conjugate vaccine that is immunogenic in children who are younger than 2 years may affect the epidemiology of occult bacteremia. This study was conducted to determine the serotype prevalence of Streptococcus pneumoniae isolates from children with occult bacteremia and to document the proportion that would be covered by the recently licensed heptavalent pneumococcal conjugate vaccine. METHODS: A cohort of 5901 children who were 2 to 24 months of age and had a temperature of >/=39.0 degrees C evaluated with a blood culture at an urban tertiary care children's hospital emergency department was studied to determine the prevalence of S pneumoniae serotypes. Patients were excluded if their immune system was suppressed, they had a diagnosis of a focal infection, they were evaluated by lumbar puncture, they were admitted to the hospital, or they died during initial evaluation. Blood cultures were inoculated into pediatric blood culture bottles and processed using an automated carbon dioxide monitoring system. All pneumococcal isolates were serotyped on the basis of capsular swelling with type-specific antisera (Quellung reaction). RESULTS: The study population consisted of 5901 patients. The overall rate of occult bacteremia was 1.9% (95% confidence interval [CI]: 1.5-2.3). S pneumoniae accounted for 92 of 111 isolates (82.9%; 95% CI: 74.6-89.4) in children with occult bacteremia. Eight pneumococcal serotypes were represented: 6A (2%), 9V (6%), 19F (6%), 18C (8%), 4 (9%), 6B (13%), 23F (15%), and 14 (42%). Serotypes 14, 6B, and 23F accounted for 69.3% (95% CI: 58.6-78.7) of typed isolates. In the cohort, 97.7% (95% CI: 92-99.7) of isolated serotypes are represented in the newly licensed heptavalent pneumococcal conjugate vaccine. The single isolated serotype that would not have been covered by the currently licensed heptavalent pneumococcal conjugate vaccine was 6A. CONCLUSIONS: S pneumoniae accounts for the vast majority of bacterial pathogens in children with occult bacteremia. As indicated by the results of this study, the heptavalent pneumococcal conjugate vaccine may prevent the majority of occult pneumococcal bacteremia episodes. The 2 cases of bacteremia with a serotype that would not have been included in the vaccine both were due to serotype 6A. It has been noted that there is potential nonvaccine serotype and subgroup cross-protection (6A from 6B) afforded to children who are immunized with the heptavalent vaccine. The high potential efficacy of the heptavalent pneumococcal conjugate vaccine for strains that cause occult bacteremia in our population may have a profound effect on the treatment of children with fever without a source. There has been an alarming and rapid emergence of antibiotic-resistant pneumococcal strains. Less pressure to use broad-spectrum antibiotics, which in turn causes further antibiotic resistance, should result. Laboratory testing and hospitalization also should be reduced. The prevalence rates determined by this study may be used as baseline data for comparison of serotype rates of occult pneumococcal bacteremia after widespread use of the heptavalent vaccine.